Clinical Report: FDA Approval of Vizz for Presbyopia Treatment

Overview

Lenz Therapeutics' Vizz (aceclidine 1.44%) eye drops received FDA approval for treating presbyopia in adults. Clinical trials demonstrated near vision improvements within 30 minutes lasting up to 10 hours, with a favorable safety profile.

Background

Presbyopia is an age-related condition characterized by diminished near vision due to reduced lens accommodation. Traditional treatments include reading glasses or surgical interventions. Vizz offers a pharmacologic approach by inducing a pinhole effect through iris sphincter muscle contraction, enhancing depth of focus without causing myopic shift. This novel mechanism aims to improve near vision conveniently and reversibly.

Data Highlights

Key Findings

• Vizz contracts the iris sphincter muscle producing a sub-2 mm pupil and pinhole effect.
• Near vision improvements were observed within 30 minutes of dosing.
• Effect duration lasted up to 10 hours post-administration.
• Met all primary and secondary near vision improvement endpoints in clinical trials.
• Common adverse events included mild, transient instillation site irritation, dim vision, and headache.
• Long-term safety confirmed over 6 months of once-daily use.

Clinical Implications

Vizz provides a non-invasive, pharmacologic option for presbyopia management that rapidly improves near vision with a sustained effect throughout the day. Its favorable safety profile and ease of use may enhance patient adherence and reduce reliance on corrective lenses. Clinicians should counsel patients on potential mild transient side effects.

Conclusion

The FDA approval of Vizz marks a significant advancement in presbyopia treatment, offering an effective and well-tolerated eye drop that improves near vision quickly and durably. It is expected to become commercially available in the US by late 2025.

References

1. Lenz Therapeutics 2024 -- FDA Approval of Vizz for Presbyopia